KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma.

This report highlights genetic alterations, in particular an acquired somatic KRAS mutation, that may occur during transdifferentiation, with additional significance of KRAS mutation as a possible therapeutic target in cases which otherwise would have limited treatment options.